Description

Stryker Corporation: The SERF SAS Acquisition & Recent Breakthroughs In Robotic Surgery

Stryker Corporation, in Q1 2024, reported an organic sales growth of 10%, underpinned by doubledigit expansion in their MedSurg and Neurotechnology segments, and high single-digit increments in Orthopaedics and Spine. Their robust U.S. performance, particularly in Instruments, Medical, Endoscopy, Trauma and Extremities, and Mako, steered their results. The momentum in growth also continued on the international front versus strong double-digit organic sales comparables from Q1 2023.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!